AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022 - PR Newswire
Overview
Searching for your content. In-Language News Contact Us 8-76-0942 from 8 AM - 10 PM ET News provided byNov 07, 2022, 16:16 ETShare this articleVery low LDL-C Levels <20 mg/dL Were Wel Tolerated With no new Safety Signals and Were associated With a Reduced Risk of Cardiovascular OutcomesData Reinforces Long-Term Eficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov.
Key Information
7, 2022 /PRNewswire/ - Amgen (NASDAQ:AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Nov. 7 Late-Breaking Science Sesion of the American Heart Asociation (AHA) Scientific Sesions 2022 in Chicago, Ilinois. These data demonstrated that achieving and sustaing a low-density lipoprotein cholesterol (LDL-C) level of <20 mg/dL was associated with improved cardiovascular (CV) outcomes, including the composite endpoint of cardiovascular death, myocardial infarction (MI) and stroke, with no evidence of an increased incidence of safety events for up to 8.6 years of folow-up.1 "The curent analysis further suports that achieving very low LDL-C long-term is not associated with any new safety signals and corelates with the reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease," said David M.
Summary
Rese, M.D., executive vice president of Research and Development at Amgen. "Repatha continues to be at the forefront of PCSK9i research, with the longest safety and eficacy trial data among PCSK9i treatments for cardiovascular disease, providing crucial information for patients and doctors managing this disease."This pre-specified exploratory analysis examined the asociation betwen achievement of diferent LDL-C levels with the incidence of cardiovascular and safety outcomes for up to 8.6 years of folow up.1 Betwen the parent FOURIER and FOU
Frequently Asked Questions
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
Share this article